What: Shares of Keryx Biopharmaceuticals (NASDAQ: KERX), a drug developer with a focus on treating renal disease, managed to fall more than 13% today with heavy trading volume on an otherwise muted day for the markets.
So what: Shares appear to be crashing today in large part because of downbeat analyst coverage, as Citi recently initiated coverage on Keryx today and rated the shares as a Sell. They even went so far as to put a target price of $1.50 on the stock, which is still far below where shares are currently trading even after factoring in todays falling price.
Analysts at large have been turning bearish on the company's stock since the start of the year, as a slew of them have lowered their price targets for the firm as sales of the company's only approved drug, Auryxia, have been slower out of the gate than many of them were expecting.
Now what: Keryx stock can't seem to get any mojo going, as earlier this summer the company's stock even managed to fall during a day that the company actually released good news.
Wall Street certainly hasn't made it easy to be long on this stock so far this year either, as a huge increase in the company's short interest has put huge selling pressure on the stock, which is now down 63% since the start of the year.
Bears have been correct on the stock so far this year, and there are certainly several reasons to believe that the company's shares will continue to decline.
While there are still reasons to believe that Keryx may have a bright future, the company's investors haven't been impressed with what they've seen since Auryxia launched and have been heading for the exits. However, I still think there are reasons to be optimistic, but I'm content to keep my money on the sidelines until we see more data about how well Auryxia is truly being received by providers, payers, and patients.
Brian Feroldi has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
More from The Motley Fool
Keryx Biopharma Down 17% Despite Drug Approval
Shares took a nosedive after the company's earnings report, but with a new FDA approval under its belt, this could be a buying opportunity for investors.
Despite FDA OK, Keryx Sinks on Gross-to-Net Surprise
The company's winning new customers, but that didn't help its third-quarter financials.
Keryx Biopharmaceuticals, Inc. Fell 8.6% In October -- Here's Why That Doesn't Matter
It was another down month for the small-cap biopharma, but this pending regulatory news promises to turn the company's fortunes around.